流脑疫苗

  • 网络meningitis;MCV
流脑疫苗流脑疫苗
  1. 靖江市部分幼儿A群流脑疫苗基础免疫效果及其影响因素分析

    Immune Effects and Its Impact Factors of Epidemic Cerebrospinal Meningitis Group A Polysaccharide Vaccine for Children in Jingjiang

  2. A+C流脑疫苗接种后抗体阳性率较接种前A群上升了104%,C群上升了160%;

    Antibody positive rate for A type and C type Neisseria meningitidis increased 104 % and 160 % respectively after vaccinating A + C epidemic meningitis vaccine .

  3. 六类人不适宜接种流脑疫苗1.中枢神经系统感染的病人不能接种。

    The patient that central nervous system affects cannot vaccinal . 2 .

  4. 健康人群的C群抗体水平随着年龄的增加降低明显,因此应做好扩大免疫规划工作,提高大年龄青少年和成年人的A+C流脑疫苗的接种率。

    The antibody levels of group C of healthy population significantly decreased with the decreasing of age . We should do more about the immunity programming to raise the vaccine inoculation rate of ( A + C ) meningitis of young people and adults .

  5. 目的对在广西壮族自治区河池市进行的成人及儿童伤寒Vi疫苗及A群流脑疫苗大规模预防接种活动的组织实施、安全注射、冷链管理、宣传发动以及接种率的结果进行描述和分析。

    OBJECTIVE To describe and analyze the implementation , safety injection , cold chain management , promotion and coverage of a mass vaccination campaign for children and adults using typhoid Vi and group A meningococcal vaccines in Hechi , Guangxi .

  6. 结果应接种对象118071人,实际接种92476人,接种率为7832%,其中伤寒Vi疫苗7687%;流脑疫苗7969%。

    Results 92,476 people of the total target population of 118 、 071 were vaccinated ; Vaccination coverage reached 78 32 % , typhoid Vi vaccine coverage reached 76 87 % and meningococcal A vaccine coverage reached 79 69 % .

  7. 方法采用组群随机试验方法确定试验组和对照组所需样本量,并组织实施大规模疫苗接种,在试验组接种伤寒Vi疫苗、对照组接种流脑疫苗。

    Methods Simple size calculation of cluster-randomized trial was used to determine the sample size of the two groups and a vaccination campaign was conducted . The study group was given typhoid Vi vaccine and the control group was given meningococcal A vaccine .

  8. 有A群流脑疫苗免疫史占82.14%,有5例流脑A+C二价疫苗免疫失败。

    82.14 % cases were vaccinated with serogroup A vaccine .

  9. 流脑疫苗的免疫史对健康人群的带菌率无直接影响。

    The immunization history of healthy population had no direct impact on the carrier rate .

  10. 疫苗总浪费率为11.10%,其中A群流脑疫苗较高。

    The overall vaccine wasted was 11.10 % with a higher wastage for meningococcal A vaccine .

  11. 有流脑疫苗免疫史的健康人群带菌率显著低于无免疫史人群。

    The carrier rate in healthy people with the history of meningitis vaccine was significantly lower than that of non-immune population .

  12. 所有这种强并非人人都能接受。六类人不适宜接种流脑疫苗1.中枢神经系统感染的病人不能接种。

    All this toughness does not sit well on everyone . The patient that central nervous system affects cannot vaccinal . 2 .

  13. [结果]五苗全程合格接种率97.36%,乙脑疫苗接种率为90.41%,流脑疫苗接种率为94.03%。

    [ Results ] The vaccination qualified rate of the five kinds of vaccines were up to 97.36 % ; the vaccination rate of JEV and Meningitis were 90.41 % and 94.03 % ;

  14. 在民工中开展流脑疫苗接种,将A+C群流脑疫苗纳入常规免疫,预防性服药和有效的应急接种等是当前控制流脑发病的有效措施。

    At present , effective measures for ECM control are carrying out ECM vaccination among peasant workers , adopting group A + C vaccine of epidemic cerebrospinal meningitis as routine immunity , and taking medicine for prevention and inoculating of effective emergency , et al .

  15. 在本组的41例病例中,发病平均年龄为(29.2±7.6)岁,其中20岁以上成人30例(73.17%),外来民工27例(65.85%),所有病例均未接种过流脑疫苗。

    Among the 41 patients , the mean age was ( 29.2 ± 7.6 ) years and ages of 30 ( 73.17 % ) cases was over 20 years old . 27 ( 65.85 % ) patients were rural workers . No vaccination was implemented in all of patients before .

  16. 合肥市18~25岁健康人群流脑免疫水平及A+C流脑疫苗免疫效果检测分析

    Epidemic Meningitis Immunity Level of Natural Population at Age of 18-25 and Analysis of Immunity Effect of A + C Epidemic Meningitis Vaccine

  17. 目的了解合肥市18~25岁人群流脑免疫水平,评价A+C流脑疫苗接种效果,为合理制定流脑A+C疫苗接种方案提供依据。

    Objective To understand epidemic meningitis immunity level of natural population at age of 18-25 and evaluate immunity effect of A + C epidemic meningitis vaccine so as to provide reasonable basis for making A + C epidemic meningitis vaccination scheme .

  18. 南京市健康儿童流脑A群和C群抗体水平监测及A+C群流脑疫苗免疫效果分析

    Monitoring on the antibody levels of meningitis serogroup A and C and immunization effect of a and C meningococcal polysaccharide vaccine among health children in Nanjing